SPARC net loss widens to Rs 41.02 cr in Q3

Pharma firm Sun Pharma Advanced Research Company Ltd (SPARC) has reported that its standalone net loss widened to Rs 41.02 crore for the third quarter ended December 31, 2015, weighed down by rise in expenses.

“The standalone net loss of the company stood at Rs 18.91 crore during the same period a year ago,” Sun Pharma Advanced Research Company Ltd said in a filing to the Bombay Stock Exchange on February 3, 2016.

However, the standalone total income of the company grew 5.9 per cent at Rs 34.1 crore during Q3 FY16, as compared to Rs 32.21 crore during the same quarter last fiscal.

Meanwhile, shares of the company closed at Rs 286.20 apiece, down 3.33 per cent, from previous close on BSE.